CTOs on the Move

MethylGene

www.methylgene.com

 
MethylGene Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.methylgene.com
  • 7220 rue Frederick-Banting
    Saint-Laurent, QC CAN H4S 2A1
  • Phone: 514.337.3333

Executives

Name Title Contact Details

Similar Companies

Protox Therapeutics Inc

Protox Therapeutics Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Becton Dickinson and Company

Becton Dickinson and Company is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jazz Pharmaceuticals

Our mission is to improve patients’ lives by identifying, developing and commercializing important specialty pharmaceutical products to address unmet patient needs. We address serious diseases, always with the goal of improving patient care. Keeping patients at the forefront of our mind inspires us to bring innovative and valuable resources to all aspects of our business for the ultimate benefit of the patients in need.

Jamaican Medical Cannabis Corporation

JMCC Group is the leading global provider of premium quality, sustainably grown, Jamaican medical cannabis products and related services to customers around the world, including licensed producers, medical researchers, product developers, manufacturers and distributors.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.